I have a lot of experience in scientific publishing and have worked on many abstracts, posters and manuscripts across a broad range of therapy areas.

I have listed below some publications where I am acknowledged as providing medical writing support or that I have authored.

Addiction medicine

Review: Alho H, et al. Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. Int J Drug Policy 2020; 76:102616.

Review: Kakko J, et al. Craving in opioid use disorder: From neurobiology to clinical practice. Front Psychiatry 2019; 10:592.

Autoimmune diseases

Symposium review: Changing the way babies eat: Supporting early allergen feeding around the world. EMJ 2022; 7:33-41. 

Primary manuscript: Sabet A, et al. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects. Rheumatol Ther 2022; 9:693-704.

Review: Peyrin-Biroulet L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021; 14:17562848211059954.

Review: Taylor PC, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med 2021; 10(3):509.

Primary manuscript: Hercogová J, et al. AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Br J Dermatol 2020; 182:316-26.

Primary manuscript: Edwards C, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol 2019; 38:3381-3390.

Poster: Hercogová J, et al. Safety, immunogenicity, and efficacy after a single switch from reference adalimumab to the proposed biosimilar MSB11022: Long-term results from a randomized, double-blind, 52-week, phase III study in moderate-to-severe plaque-type psoriasis patients. Presented at the American Academy of Dermatology Annual Meeting 2019. 

Review: Baumgart DC, et al. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front Pharmacol 2019; 10:279.

Review: Edwards CJ, et al. Switching to biosimilars: Current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 2019; 19:1001-14.

Cardiology

 

HEOR: Klein H and Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. J Med Econ 2017; 20:640-45.

Diabetes

 

Primary manuscript: Harris SB et al. The educational impact of online, faculty-led continuing medical education programs in type 2 diabetes: An analysis of changes in the knowledge, competence, and performance of healthcare professionals. JMIR Med Educ 2022; 8(4):e40520.

HEOR: Nguyen-Thi H-Y, et al. Cost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the ADVANCE trial in Vietnam. Front Public Health 2020; 8:56203.

Diagnostics

Primary manuscript: Taffertshofer K et al. Design and performance characteristics of the Elecsys Anti-SARS-CoV-2 S assay. medRxiv 2022.07.04.22277103; doi: https://doi.org/10.1101/2022.07.04.22277103.

Primary manuscript: Kirste I et al. Quantifying the vaccine-induced humoral immune response to spike-receptor binding domain as a surrogate for neutralization testing following mRNA-1273 (Spikevax) vaccination against COVID-19. Infect Dis Ther 2022. Online ahead of print.

Primary manuscript: Hinchliffe E, Carter S, et al. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 15:913-914.

Primary manuscript: Carter S, et al. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012; 49:570-9.

Haemophilia

Conference review: Gene therapy in haemophilia: Updates from clinical trials and insights to future technologies. EMJ 2022; 10[5]:2-12. 

 

Case series: Klamroth R, et al. Illustrative cases from the pathfinder clinical trials of patients with hemophilia A treated with turoctocog alfa pegol (N8-GP). Pat Pref Adher 2021; 15: 2443-54.

Infectious diseases

Primary manuscript: Bosheva M, et al. A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatr Infect Dis 2021; 40:e222-9.

Primary manuscript: Overcash JS, et al.  Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a Phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis 2021; 73:e1507-17.

Secondary manuscript: Welte et al. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. Future Microbiol 2021; 16:543-555.

Protocol: Hamed K, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial.  Future Microbiol 2020; 15:35-48.

Secondary manuscript: Hamed K, et al.  No evidence for ceftobiprole-induced immune hemolytic anemia in three Phase 3 clinical trials. Infect Drug Resist 2020; 13:3461.

RWE: Stemler J, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. Mycoses 2020; 63:1060-68.

Oncology

Symposium review: Management of thrombosis in high-risk patients: Focus on cancer-associated thrombosis. EMJ 2022; 7[3]:30-39.

KOL interview: Gibbs H, Klok FA. New developments, data, and guideline updates: Direct oral anticoagulants for the treatment of venous thromboembolism associated with cancer - interviews with key opinion leaders. EMJ 2022;10(Suppl 3):2-8.

 

Primary manuscript: Hock AK, Vigneron A, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 2011; 30:4921-30.

Primary manuscript: Stindt MH, Carter S, et al. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 2011; 10:3176-88.

Review: Carter S and Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24.

Primary manuscript: Carter S and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008; 7:2519-28.

Review: Carter S and Vousden KH. A role for Numb in p53 stabilization. Genome Biol 2008; 9:221.

Primary manuscript: Carter S, et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biol 2007; 9:428-35.

Primary manuscript: Carter S, et al. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004; 279:52835-9.

Review: Hammond DE, Carter S, et al. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 2004; 286:21-44.

Primary manuscript: Hammond DE, Carter S, et al. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003; 14: 1346-54.

Pulmonary hypertension

Secondary manuscript: Chin KM, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. Circulation 2019; 139:2440-50.

Secondary manuscript: Torbicki A, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases. Circ Cardiovasc Qual Outcomes 2019; 12:e005095.

 

Primary manuscript: Berger RMF, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017; 83:1734-44.